Candel Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CADL research report →
Companywww.candeltx.com
Candel Therapeutics, Inc. , a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.
- CEO
- Paul-Peter Tak
- IPO
- 2021
- Employees
- 38
- HQ
- Needham, MA, US
Price Chart
Valuation
- Market Cap
- $434.80M
- P/E
- -9.08
- P/S
- 0.00
- P/B
- 3.58
- EV/EBITDA
- -4.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -60.42%
- ROIC
- -28.89%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-38,182,000 · 30.80%
- EPS
- $-0.72 · 58.62%
- Op Income
- $-48,266,000
- FCF YoY
- -43.86%
Performance & Tape
- 52W High
- $9.27
- 52W Low
- $4.35
- 50D MA
- $6.10
- 200D MA
- $5.65
- Beta
- -0.58
- Avg Volume
- 1.77M
Get TickerSpark's AI analysis on CADL
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | Manning Paul B | other | 4,618 |
| Mar 31, 26 | PAPA JOSEPH C | other | 2,795 |
| Mar 31, 26 | Loggia Nicoletta | other | 779 |
| Feb 23, 26 | Manning Paul B | buy | 550,458 |
| Jan 26, 26 | Tyagarajan Seshu | other | 154,000 |
| Jan 26, 26 | Nichols William Garrett | other | 136,500 |
| Jan 26, 26 | Schoch Charles | other | 232,000 |
| Jan 26, 26 | Tak Paul Peter | other | 629,000 |
| Jan 26, 26 | Barone Francesca | other | 232,000 |
| Jul 28, 25 | Nichols William Garrett | other | 937 |
Our CADL Coverage
We haven't published any research on CADL yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CADL Report →